Based on the close relationship of LXR and downstream of EGFR signaling pathway, and furtherly considering our preliminary results, we hypothesis that LXR agonist GW3965 can reverse the acquired gefitinib resistance by inhibiting NF-κB expression, and the research would provide a useful option for clinical treatment of acquired gefitinib resistant lung cancer. This evidence concerns the gene NFKB1 and lung carcinoma.